Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Robohogs	10/21/2008 7:54:36 AM
	Read Replies (1) of 10345

Numbers EDITED US commcl patients were 19.5 vs 17.8K in Q2. That is 10% QoQ growth. ROW was 15.3 vs. 13.4 still faster than US growth. There are 700 trial patients vs. 600. Numbers in Q1 were 15.3K in US, 10.2K in ROW and 600 in trials. So growth trends in numbers are: 2.5K during Q2 in US vs. 1.7K in Q3. For Europe you get 3.2K in Q2 and 1.9K in Q3. Jon

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next